Which nursing intervention is most appropriate for a client with Alzheimers disease who has frequent episodes emotional liability?

1. Deutsch LH, Rovner BW. Agitation and other noncognitive abnormalities in Alzheimer’s disease. Psychiatr Clin North Am. 1991;14:341–51. [PubMed] [Google Scholar]

2. World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders. Clinical descriptions and diagnostic guidelines. Geneva: World Health Organization; 1992. [Google Scholar]

3. Spalletta G, Baldinetti F, Buccione I, Fadda L, Perri R, Scalmana S, Serra L, Caltagirone C. Cognition and behaviour are independent and heterogeneous dimensions in Alzheimer’s disease. J Neurol. 2004;251:688–95. [PubMed] [Google Scholar]

4. Hersch EC, Falzgraf S. Management of the behavioral and psychological symptoms of dementia. Clin Interv Aging. 2007;2:611–21. [PMC free article] [PubMed] [Google Scholar]

5. Benoit M, Staccini P, Brocker P, Benhamidat T, Bertogliati C, Lechowski L, et al. Behavioral and psychologic symptoms in Alzheimer’s disease: results of the REAL. FR study. Rev Med Interne. 2003;24:319s–24s. [PubMed] [Google Scholar]

6. Torta R, Badino E, Scalabrino A. Therapeutic strategies for behavioral and psychological symptoms (BPSD) in demented patients. Arch Gerontol Geriatr Suppl. 2004;9:443–54. [PubMed] [Google Scholar]

7. Dorey JM, Beauchet O, Thomas Anterion C, Rouch I, Krolak-Salmon P, Gaucher J, et al. Behavioral and psychological symptoms of dementia and bipolar spectrum disorders: review of the evidence of a relationship and treatment implications. CNS Spectr. 2008;13:796–803. [PubMed] [Google Scholar]

8. Adams BE, Tunis SL, Edell WS. Assessing antipsychotic effectiveness in dementia with the factor structure of the Psychogeriatric Dependency Rating Scale (PGDRS) J Am Med Dir Assoc. 2003;4:61–6. [PubMed] [Google Scholar]

9. Parnetti L, Amici S, Lanari A, Gallai V. Pharmacological treatment of non-cognitive disturbances in dementia disorders. Mech Ageing Dev. 2001;122:2063–9. [PubMed] [Google Scholar]

10. Herrmann N. Recommendations for the management of behavioral and psychological symptoms of dementia. Can J Neurol Sci. 2001;28:S96–107. [PubMed] [Google Scholar]

11. Rabins PV, Mace NL, Lucas NJ. The impact of dementia on the family. JAMA. 1982;248:333–5. [PubMed] [Google Scholar]

12. Kar N. Behavioural and Psychological Symptoms of Dementia. In: Kar N, Jolley D, Misra N, editors. Handbook of Dementia. Hyderabad: Paras Medical Publisher; 2005. pp. 54–74. [Google Scholar]

13. Wynn ZJ, Cummmings JL. Cholinesterase inhibitors therapies and neuropsychiatric manifestations of Alzheimer’s disease. Dement Geriatr Cogn Disord. 2004;17:100–8. [PubMed] [Google Scholar]

14. Herrmann N, Lanctôt KL, Sambrook R, Lesnikova N, Hébert R, McCracken P, et al. The contribution of neuropsychiatric symptoms to the cost of dementia care. Int J Geriatr Psychiatry. 2006;21:972–6. [PubMed] [Google Scholar]

15. Beeri MS, Werner P, Davidson M, Noy S. The cost of behavioral and psychological symptoms of dementia (BPSD) in community dwelling Alzheimer’s disease patients. Int J Geriatr Psychiatry. 2002;17:403–8. [PubMed] [Google Scholar]

16. Kluger A, Ferris SH. Scales for the assessment of Alzheimer’s disease. Psychiatr Clin North Am. 1991;14:309–26. [PubMed] [Google Scholar]

17. Neil W, Bowie P. Carer burden in dementia--assessing the impact of behavioural and psychological symptoms via self-report questionnaire. Int J Geriatr Psychiatry. 2008;23:60–4. [PubMed] [Google Scholar]

18. Lyketsos CG, Steinberg M, Tschanz JT, Norton MC, Steffens DC, Breitner JC. Mental and behavioral disturbances in dementia: Findings from the Cache County Study on Memory in Aging. Am J Psychiatry. 2000;157:708–14. [PubMed] [Google Scholar]

19. Wancata J. Efficacy of risperidone for treating patients with behavioral and psychological symptoms of dementia. Int Psychogeriatr. 2004;16:107–15. [PubMed] [Google Scholar]

20. Vega UM, Marinho V, Engelhardt E, Laks J. Neuropsychiatric symptoms in dementias: preliminary report of a prospective outpatient evaluation in Brazil. Arq Neuropsiquiatr. 2007;65:498–502. [PubMed] [Google Scholar]

21. Lytetsos CG, Lee HB. Diagnosis and treatment of depression in Alzheimer’s disease: A practical update for the clinician. Dementia and Geriatric Cognitive Disorders. 2004;17:55–64. [PubMed] [Google Scholar]

22. Fuh JL. Study of behavioral and psychological symptoms of dementia in Taiwan. Acta Neurol Taiwan. 2006;15:154–60. [PubMed] [Google Scholar]

23. Engelborghs S, Maertens K, Nagels G, Vloeberghs E, Mariën P, Symons A, et al. Neuropsychiatric symptoms of dementia: cross-sectional analysis from a prospective, longitudinal Belgian study. Int J Geriatr Psychiatry. 2005;20:1028–37. [PubMed] [Google Scholar]

24. Piccininni M, Di Carlo A, Baldereschi M, Zaccara G, Inzitari D. Behavioral and psychological symptoms in Alzheimer’s disease: frequency and relationship with duration and severity of the disease. Dement Geriatr Cogn Disord. 2005;19:276–81. [PubMed] [Google Scholar]

25. Lyketsos CG, Sheppard JM, Steinberg M, Taschanz JA, Norton mC, Steffens DC, et al. Neuropsychiatric disturbance in ALZHEIMER’S disease cluster into three groups: The Cache Countty Study. Int J Geriatr Psychiatry. 2001;16:1043–53. [PubMed] [Google Scholar]

26. Lam LC, Leung T, Lui VW, Leung VP, Chiu HF. Association between cognitive function, behavioral syndromes and two-year clinical outcome in Chinese subjects with late-onset alzheimer’s disease. Int Psychogeriatr. 2006;18:517–26. [PubMed] [Google Scholar]

27. Ferri CP, Ames D, Prince M. 10/66 Dementia Research Group. Behavioral and psychological symptoms of dementia in developing countries. Int Psychogeriatr. 2004;16:441–59. [PubMed] [Google Scholar]

28. Cohen-Mansfield J. Nonpharmacologic interventions for inappropriate behaviours in dementia: A review, summary, and critique. Focus: The Journal of Lifelong Learning in Psychiatry. 2004;2:288–308. [Google Scholar]

29. Ito T, Meguro K, Akanuma K, Meguro M, Lee E, Kasuya M, et al. Behavioral and psychological symptoms assessed with the BEHAVE-AD-FW are differentially associated with cognitive dysfunction in Alzheimer’s disease. J Clin Neurosci. 2007;14:850–5. [PubMed] [Google Scholar]

30. Shah A, Ellanchenny N, Suh GH. A comparative study of behavioral and psychological signs and symptoms of dementia in patients with dementia referred to psychogeriatric services in Korea and the United Kingdom. Int Psychogeriatr. 2004;16:219–36. [PubMed] [Google Scholar]

31. Kar N, Sharma PSVN, Sengupta S. Behavioural and psychological symptoms in dementia - clinical features in an Indian population. Int J Geriatr Psychiatry. 2001;16:540–1. [PubMed] [Google Scholar]

32. Senanarong V, Cummings JL, Fairbanks L, Mega M, Masterman DM, O’Connor SM, et al. Agitation in Alzheimer’s disease is a manifestation of frontal lobe dysfunction. Dement Geriatr Cogn Disord. 2004;17:14–20. [PubMed] [Google Scholar]

33. Reisberg B, Borenstein J, Salob SP, Ferris SH, Franssen E, Georgotas A. Behavioural symptoms in Alzheimer’s disease: Phenomenology and treatment. J Clin Psychiatry. 1987;48:9–15. [PubMed] [Google Scholar]

34. Sourander P, Sjogren H. The concept of Alzheimer’s disease and its clinical implications. In: WolstenHolme GE, O’Connor M, editors. Alzheimer’s disease. Ciba Foundation Symposium. London: Churchill; 1970. [Google Scholar]

35. Cheong JA. An evidence-based approach to the management of agitation in the geriatric patient. Focus: The Lifelong Learning in Psychiatry. 2004;2:197–205. [Google Scholar]

36. Lishman WA. Organic Psychiatry: The Psychological Consequences of Cerebral Disorder. Oxford: Blackwell Scientific Publication; 1987. [Google Scholar]

37. Boyle PA, Malloy PF. Treating apathy in Alzheimer’s disease. Dement Geriatr Cogn Disord. 2004;17:91–9. [PubMed] [Google Scholar]

38. Burns A, Levy R. Clinical diversity in Late Onset alzheimer’s Disease, Maudsley Monograph No 34. Oxford: Oxford University Press; 1992. [Google Scholar]

39. Sultzer DL. Psychosis and antipsychotic medications in Alzhimer’s Disease: Clinical management and research perspectives. Dement Geriatr Cogn Disord. 2004;17:78–90. [PubMed] [Google Scholar]

40. Kar N, Sengupta S, Sharma PS. Noncognitive abnormalities in dementia. Paper presented at 14th International Conferenec of Alzheimer’s Disease International, September 24-27, 1998, at Cochin [Google Scholar]

41. Borroni B, Agosti C, Padovani A. Behavioral and psychological symptoms in dementia with Lewy-bodies (DLB): frequency and relationship with disease severity and motor impairment. Arch Gerontol Geriatr. 2008;46:101–6. [PubMed] [Google Scholar]

42. Chiu MJ, Chen TF, Yip PK, Hua MS, Tang LY. Behavioral and psychologic symptoms in different types of dementia. J Formos Med Assoc. 2006;105:556–62. [PubMed] [Google Scholar]

43. Teri L, Larson EB, Reifler BV. Behavioural Disturbance in dementia of Alzheimer’s type. Journal of the American Geriatric Society. 1988;36:1–6. [PubMed] [Google Scholar]

44. Hall GR. Caring for people with Alzheimer’s disease using the conceptualmodel of progressively lowered stress threshold in the clinical setting. Nurs Clin North Am. 1994;29:129–41. [PubMed] [Google Scholar]

45. Archer N, Brown RG, Reeves SJ, Boothby H, Nicholas H, Foy C, et al. Premorbid personality and behavioral and psychological symptoms in probable Alzheimer disease. Am J Geriatr Psychiatry. 2007;15:202–13. [PubMed] [Google Scholar]

46. Lanctôt KL, Herrmann N, Mazzotta P. Role of serotonin in the behavioral and psychological symptoms of dementia. J Neuropsychiatry Clin Neurosci. 2001;13:5–21. [PubMed] [Google Scholar]

47. Herrmann N, Lanctôt KL, Khan LR. The role of norepinephrine in the behavioral and psychological symptoms of dementia. J Neuropsychiatry Clin Neurosci. 2004;16:261–76. [PubMed] [Google Scholar]

48. Tabet N, Rafi H, Weaving G, Lyons B, Iversen SA. Behavioural and psychological symptoms of Alzheimer type dementia are not correlated with plasma homocysteine concentration. Dement Geriatr Cogn Disord. 2006;22:432–8. [PubMed] [Google Scholar]

49. Engelborghs S, Vloeberghs E, Le Bastard N, Van Buggenhout M, Mariën P, Somers N, et al. The dopaminergic neurotransmitter system is associated with aggression and agitation in frontotemporal dementia. Neurochem Int. 2008;52:1052–60. [PubMed] [Google Scholar]

50. Pritchard AL, Pritchard CW, Bentham P, Lendon CL. Investigation of the Role of the Dopamine Transporter in Susceptibility to Behavioural and Psychological Symptoms of Patients with Probable Alzheimer’s Disease. Dement Geriatr Cogn Disord. 2008;26:257–60. [PubMed] [Google Scholar]

51. Pritchard AL, Pritchard CW, Bentham P, Lendon CL. Role of serotonin transporter polymorphisms in the behavioural and psychological symptoms in probable Alzheimer disease patients. Dement Geriatr Cogn Disord. 2007;24:201–6. [PubMed] [Google Scholar]

52. Pritchard AL, Harris J, Pritchard CW, Coates J, Haque S, Holder R, et al. The effect of the apolipoprotein E gene polymorphisms and haplotypes on behavioural and psychological symptoms in probable Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 2007;78:123–6. [PMC free article] [PubMed] [Google Scholar]

53. Mortimer JA, Ebbitt B, Jun SP, Finch MD. Predictors of cognitive and functional progression in patients with probable Alzheimer’s disease. Neurology. 1992;42:1689–96. [PubMed] [Google Scholar]

54. Marin RS, Beiedrzycki RC, Firinciogullari S. Reliability and validity of the Apathy Evaluation Scale. Psychiatry Res. 1991;38:143–62. [PubMed] [Google Scholar]

55. van der Kam P, Mol F, Wimmers MF. Beoordelingsschaal voor oudere patienten (BOP) Deventer: Van Loghum Slaterus; 1971. [Google Scholar]

56. Tariot PN, Mack JL, Patterson MB, Edland SD, Weiner MF, Fillenbaum G, et al. The behaviour rating scale for dementia of the Consortium to Establish a Registry for Alzheimer’s disease. Am J psychiatry. 1995;152:1349–57. [PubMed] [Google Scholar]

57. Cohen-Mansfield J, Marx MS, Rosenthal AS. A description of agitation in nursing home J Gerontol. 1989;44:M77–84. [PubMed] [Google Scholar]

58. Alexopoulos GS Abrams RC, Young RC, Shamoian CA. Cornell scale for depression in dementia. Biol Psychiatry. 1988;23:271–84. [PubMed] [Google Scholar]

59. Grace J, Malloy PF. Frontal System Behaviour Scale (FrSBe): Professional Manual. Lutz: Psychological Assessment Resources. 2001 [Google Scholar]

60. Cummings JL. The Neuropsychiatric Inventory: Assessing psychopathology in dementia patients. Neurology. 1997;48:S10–6. [PubMed] [Google Scholar]

61. Wood S, Cummings JL, Hsu MA, Barclay T, Wheatley MV, Yarema KT, Schnelle JF. The use of the neuropsychiatric inventory in nursing home residents: Characterization and measurement. Am J Geriatr Psychiatry. 2000;8:75–83. [PubMed] [Google Scholar]

62. Robert PH, Clarinet S, Benoit M, Koutaich J, Bertogliati C, Tible O, et al. The apathy inventory: Assessment of apathy and awareness in Alzheimer’s disease, Parkinson’s disease and mild cognitive impairment. Int J Geriatr Psychaitry. 2002;17:1099–105. [PubMed] [Google Scholar]

63. Haider I, Shah A. A pilot study of behavioural and psychological signs and symptoms of dementia in patients of Indian sub-continent origin admitted to a dementia day hospital in the United Kingdom. Int J Geriatr Psychiatry. 2004;19:1195–204. [PubMed] [Google Scholar]

64. Omelan C. Approach to managing behavioural disturbances in dementia. Can Fam Physician. 2006;52:191–9. [PMC free article] [PubMed] [Google Scholar]

65. Kar N. Management of Behavioural and Psychological Symptoms of Dementia. In: Kar N, Jolley D, Misra B, editors. Handbook of Dementia. Hyderabad: Paras Medical Publisher; 2005. pp. 204–27. [Google Scholar]

66. Cohen-Mansfield J, Werner P. Management of verbally disruptive behaviours in nursing home residents. J Gerontol Med Sci. 1997;52:M369–77. [PubMed] [Google Scholar]

67. Zisselman MH, Rovenoer BW, Shmuey Y, Ferrie P. A pet therapy intervention with geriatric psychiatry inpatients. Am J Occup Ther. 1996;50:47–51. [PubMed] [Google Scholar]

68. Fritz C, Farver T, Kass P, Hart LA. Association with companion animals and the expression of noncognitive symptoms in Alzheimer’s patients. J Nerv Ment Dis. 1995;183:459–63. [PubMed] [Google Scholar]

69. Palmer CV, Adams SW, Bourgeois M, Durrant J, Rossi M. Reduction in care-giver-identified problem behaviour in patients with Alzheimer disease post hearing-aid fitting. J Speech Lang Hear Res. 1999;42:312–28. [PubMed] [Google Scholar]

70. Nguyen QA, Paton C. The use of aromatherapy to treat behavioural problems in dementia. Int J Geriatr Psychiatry. 2008;23:337–46. [PubMed] [Google Scholar]

71. Alessi Yoon CA, Yoon EJ, Schnelle JF, Al-Samarrai NR, Cruise PA. A randomized trial of a combined physical activity and environmental intervention in nursing home residents: do sleep and agitation improve? J Am Geriatr Soc. 1999;47:784–91. [PubMed] [Google Scholar]

72. Skjerve A, Bjorvatn B, Holsten F. Light therapy for behavioural and psychological symptoms of dementia. Int J Geriatr Psychiatry. 2004;19:516–22. [PubMed] [Google Scholar]

73. Raglio A, Bellelli G, Traficante D, Gianotti M, Ubezio MC, Villani D, et al. Efficacy of music therapy in the treatment of behavioral and psychiatric symptoms of dementia. Alzheimer Dis Assoc Disord. 2008;22:158–62. [PubMed] [Google Scholar]

74. Woodhead EL, Zarit SH, Braungart ER, Rovine MR, Femia EE. Behavioral and psychological symptoms of dementia: the effects of physical activity at adult day service centers. Am J Alzheimers Dis Other Demen. 2005;20:171–9. [PubMed] [Google Scholar]

75. Femia EE, Zarit SH, Stephens MA, Greene R. Impact of adult day services on behavioral and psychological symptoms of dementia. Gerontologist. 2007;47:775–88. [PubMed] [Google Scholar]

76. Mentes JC, Ferrario J. Calming aggressive reactions: a preventive program. J Gerontol Nurs. 1989;15:22–7. [PubMed] [Google Scholar]

77. McCallion P, Toseland RW, Lacey D, Banks S. Educating nursing assistants to communicate more effectively with nursing home residents with dementia. Gerontologist. 1999;39:546–58. [PubMed] [Google Scholar]

78. Selbaek G, Engedal K. Atypical antipsychotics in elderly patients with dementia. Tidsskr Nor Laegeforen. 2008;128:1060–1. [PubMed] [Google Scholar]

79. Profenno LA, Tariot PN. Pharmacologic management of agitation in Alzheimer’s disease. Dement Geriatr Cogn Disord. 2004;17:65–77. [PubMed] [Google Scholar]

80. Kasckow JW, Mulchahey JJ, Mohamed S. Using antipsychotics in patients with dementia. Current psychiatry. 2004;3:55–64. [Google Scholar]

81. Rosler M. The efficacy of cholinesterase inhibitors in treating the behavioural symptoms of dementia. Int J Clin Pract Suppl. 2002;127:20–36. [PubMed] [Google Scholar]

82. Bullock R. Treatment of behavioural and psychiatric symptoms in dementia: implications of recent safety warnings. Curr Med Res Opin. 2005;21:1–10. [PubMed] [Google Scholar]

83. Rozzini L, Chilovi BV, Bertoletti E, Conti M, Delrio I, Trabucchi M, Padovani A. Cognitive and psychopathologic response to rivastigmine in dementia with Lewy bodies compared to Alzheimer’s disease: a case control study. Am J Alzheimers Dis Other Demen. 2007;22:42–7. [PubMed] [Google Scholar]

84. Rosler M, Retz W, Retz-Junginger P, Dennier HJ. Effects of two-year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer’s disease. Behav Neurol. 1988;11:211–6. [PubMed] [Google Scholar]

85. Dartigues JF, Goulley F, Bourdeix I, Péré JJ, Barberger-Gateau P. Rivastigmine in current clinical practice in patients with mild to moderate Alzheimer’s disease. Rev Neurl (Paris) 2002;158:807–12. [PubMed] [Google Scholar]

86. Finkel SI. Effects of rivastigmine on behavioral and psychological symptoms of dementia in Alzheimer’s disease. Clin Ther. 2004;26:980–90. [PubMed] [Google Scholar]

87. Cummings JL. Use of cholinesterase inhibitors in clinical practice: evidence based recommendations. Am J Geriatr Psychiatry. 2003;11:131–45. [PubMed] [Google Scholar]

88. Tariot PN, Cummings JL, Katz IR, Mintzer J, Perdomo CA, Schwam EM, et al. A Randomised double blind placebo controlled study of the efficacy and safety of donepezil in patients with Alzheimer’s disease in the nursing home setting. J Am Geratr Soc. 2001;49:1590–9. [PubMed] [Google Scholar]

89. Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E, et al. A 24-week, randomized double-blind study of donepezil in moderate to severe Alzheimer’s disease. Neurology. 2001;57:613–20. [PubMed] [Google Scholar]

90. Gauthier S, Fedman H, Hecker J, Vellas B, Ames D, Subbiah P, et al. Efficacy of donepezil on behavioural symptoms in patients with moderate to severe Alzheimer’s disease. Int Psychogeriatr. 2002;14:389–404. [PubMed] [Google Scholar]

91. Small GW, Donohue JA, Brooks RL. An economic evaluation of donepezil in the treatment of Alzheimer’s disease. Clin Ther. 1998;20:838–50. [PubMed] [Google Scholar]

92. Paleacu D, Mazeh D, Mirecki I, Even M, Barak Y. Donepezil for the treatment of behavioral symptoms in patients with Alzheimer’s disease. Clin Neuropharmacol. 2002;25:313–7. [PubMed] [Google Scholar]

93. Tangwongchai S, Thavichachart N, Senanarong V, Poungvarin N, Phanthumchinda K, Praditsuwan R, et al. Galantamine for the Treatment of BPSD in Thai Patients With Possible Alzheimer’s Disease With or Without Cerebrovascular Disease. Am J Alzheimers Dis Other Demen. 2008 Oct 9. [Epub ahead of print] [PubMed] [Google Scholar]

94. Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C. A 5-month, randomised, placebo controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology. 2000;54:2269–76. [PubMed] [Google Scholar]

95. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ, et al. Memantine in moderate to severe Alzheimer’s disease. N Engl J Med. 2003;348:1333–41. [PubMed] [Google Scholar]

96. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004;291:317–24. [PubMed] [Google Scholar]

97. Miller LJ. The use of cognitive enhancers in behavioral disturbances of Alzheimer’s disease. Consult Pharm. 2007;22:754–62. [PubMed] [Google Scholar]

98. Wooltoton E. Risperidone (Risperdal): Increased rate of cerebrovascular events in dementia trials. CMAJ. 2002;167:1269–70. [PMC free article] [PubMed] [Google Scholar]

99. Angelini A, Bendini C, Neviani F, Neri M. Behavioral and psychological symptoms of dementia (BPSD) in elderly demented subjects: is the long lasting use of atypical antipsychotic drugs useful and safe? Arch Gerontol Geriatr. 2007;44:35–43. [PubMed] [Google Scholar]

100. Greve M, O’Connor D. A survey of Australian and New Zealand old age psychiatrists’ preferred medications to treat behavioral and psychological symptoms of dementia (BPSD) Int Psychogeriatr. 2005;17:195–205. [PubMed] [Google Scholar]

101. Sultzer DL, Gray KF, Gunay I, Berisford MA, Mahler ME. A double blind comparison of trazodone and haloperidol for treatment of agitation in patients with dementia. Am J Geriatr Psychiatry. 1997;5:60–9. [PubMed] [Google Scholar]

102. Durán JC, Greenspan A, Diago JI, Gallego R, Martinez G. Evaluation of risperidone in the treatment of behavioral and psychological symptoms and sleep disturbances associated with dementia. Int Psychogeriatr. 2005;17:591–604. [PubMed] [Google Scholar]

103. Rabinowitz J, Katz IR, De Deyn PP, Brodaty H, Greenspan A, Davidson M. Behavioral and psychological symptoms in patients with dementia as a target for pharmacotherapy with risperidone. J Clin Psychiatry. 2004;65:1329–34. [PubMed] [Google Scholar]

104. Katz I, de Deyn PP, Mintzer J, Greenspan A, Zhu Y, Brodaty H. The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer’s disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials. Int J Geriatr Psychiatry. 2007;22:475–84. [PubMed] [Google Scholar]

105. Rainer M, Haushofer M, Pfolz H, Struhal C, Wick W. Quetiapine versus risperidone in elderly patients with behavioural and psychological symptoms of dementia: efficacy, safety and cognitive function. Eur Psychiatry. 2007;22:395–403. [PubMed] [Google Scholar]

106. Brodaty H, Ames D, Snowdon J, Woodward M, Kirwan J, Clarnette R, et al. A randomized placebo controlled trial of risperidone for the treatment of aggression, agitation and psychosis in dementia. J Clin Psychiatry. 2003;64:134–43. [PubMed] [Google Scholar]

107. Laks J, Engelhardt E, Marinho V, Rozenthal M, Souza FC, Bacaltchuk J, Stoppe A, Jr, Ferreira RC, Bottino C, Scalco M. Efficacy and safety of risperidone oral solution in agitation associated with dementia in the elderly. Arq Neuropsiquiatr. 2001;59:859–64. [PubMed] [Google Scholar]

108. Onor ML, Saina M, Trevisiol M, Cristante T, Aguglia E. Clinical experience with risperidone in the treatment of behavioral and psychological symptoms of dementia. Prog Neuropsychopharmacol Biol Psychiatry. 2007;30;31:205–9. [PubMed] [Google Scholar]

109. Chan WC, Lam LC, Choy CN, Leung VP, Li SW, Chiu HF. A double-blind randomised comparison of risperidone and haloperidol in the treatment of behavioural and psychological symptoms in Chinese dementia patients. Int J Geriatr Psychiatry. 2001;16:1156–62. [PubMed] [Google Scholar]

110. Suh GH, Greenspan AJ, Choi SK. Comparative efficacy of risperidone versus haloperidol on behavioural and psychological symptoms of dementia. Int J Geriatr Psychiatry. 2006;21:654–60. [PubMed] [Google Scholar]

111. Suh GH, Son HG, Ju YS, Jcho KH, Yeon BK, Shin YM, Kee BS, Choi SK. A randomized, double-blind, crossover comparison of risperidone and haloperidol in Korean dementia patients with behavioral disturbances. Am J Geriatr Psychiatry. 2004;12:509–16. [PubMed] [Google Scholar]

112. Lonergan E, Luxenberg J, Colford J. Haloperidol for agitation in dementia. Cochrane Database Syst Rev. 2002;2:CD002852. [PubMed] [Google Scholar]

113. Street JS, Clark WS, Kadam DL, Mitan SJ, Juliar BE, Feldman PD, et al. Long-term efficacy of olanzapine in the control of psychotic and behavioural symptoms in nursing home patients with Alzheimer’s dementia. Int J Geriatr Psychiatry. 2001;16:S62–70. [PubMed] [Google Scholar]

114. Meehan KM, Wang H, David SR, Nisivoccia JR, Jones B, Beasley CM, Jr, et al. Comparison of rapidly acting intramuscular olanzapine, lorazepam and placebo: a double blind randomised study in acutely agitated patients with dementia. Neuropsychopharmacology. 2002;26:494–504. [PubMed] [Google Scholar]

115. Moretti R, Torre P, Antonello RM, Cattaruzza T, Cazzato G. Olanzapine as a possible treatment of behavioral symptoms in vascular dementia: risks of cerebrovascular events. A controlled, open-label study. J Neurol. 2005;252:1186–93. [PubMed] [Google Scholar]

116. Deberdt WG, Siegal A, Ahl J, Meyers AL, Landbloom R. Effect of olanzapine on cognition during treatment of behavioral and psychiatric symptoms in patients with dementia: a post-hoc analysis. Int J Geriatr Psychiatry. 2008;23:364–9. [PubMed] [Google Scholar]

117. Fujikawa T, Takahashi T, Kinoshita A, Kajiyama H, Kurata A, Yamashita H, et al. Quetiapine treatment for behavioral and psychological symptoms in patients with senile dementia of Alzheimer type. Neuropsychobiology. 2004;49:201–4. [PubMed] [Google Scholar]

118. Scharre DW, Chang SI. Cognitive and behavioral effects of quetiapine in Alzheimer disease patients. Alzheimer Dis Assoc Disord. 2002;16:128–30. [PubMed] [Google Scholar]

119. Davis P, Baskys A. Quetiapine effectively reduces psychotic symptoms in patients with Lewy body dementia: An advantage of the unique pharmacological profile? Brain Aging. 2002;2:49–53. [Google Scholar]

120. Paleacu D, Barak Y, Mirecky I, Mazeh D. Quetiapine treatment for behavioural and psychological symptoms of dementia in Alzheimer’s disease patients: a 6-week, double-blind, placebo-controlled study. Int J Geriatr Psychiatry. 2008;23:393–400. [PubMed] [Google Scholar]

121. Konovalov S, Muralee S, Tampi RR. Anticonvulsants for the treatment of behavioral and psychological symptoms of dementia: a literature review. Int Psychogeriatr. 2008;20:293–308. [PubMed] [Google Scholar]

122. Tariot PN, Shneider L, Intzer J, et al. Safety and tolerability of divalproex sodium for the treatment of signs and symptoms of mania in elderly patients with dementia: Results of a double-blind placebo controlled trial. Curr Ther Res. 2001;62:51–67. [Google Scholar]

123. Porsteinsson AP. Divalproex sodium for the treatment of behavioural problems associated with dementia in the elderly. Drugs Aging. 2006;23:877–86. [PubMed] [Google Scholar]

124. Sival RC, Haffmans PM, Jansen PA, Duursma SA, Eikelenboom P. Sodium valproate in the treatment of aggressive behaviour in patients with dementia - A randomized placebo-controlled clinical trial. Int J Geriatr Psychiatry. 2002;17:579–85. [PubMed] [Google Scholar]

125. Tariot PN, Erb R, Podgorski CA, Cox C, Patel S, Jakimovich L, et al. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am J Psychiatry. 1998;155:54–61. [PubMed] [Google Scholar]

126. Olin JT, Fox LS, Pawluczyk S, Taggart NA, Schneider LS. A pilot randomised trial of carbamazepine for behavioural symptoms in treatment-resistant outpatient with Alzheimer’s disease. Am J Geriatr Psychiatry. 2001;9:400–5. [PubMed] [Google Scholar]

127. Miller LJ. Gabapentin for treatment of behavioral and psychological symptoms of dementia. Ann Pharmacother. 2001;35:427–31. [PubMed] [Google Scholar]

128. Finkel SI, Mintzer JE, Dysken M, Krishnana KR, Burt T, McRae T. A randomized placebo-controlled study of the efficacy and safety of sertraline in the treatment of the behavioural manifestation of Alzheimer’s disease in outpatients treated with donepezil. Int J Geriatr Psychiatry. 2004;19:9–18. [PubMed] [Google Scholar]

129. Gaber S, Ronozoli S, Bruno A, Biagi A. Sertraline versus small doses of haloperidol in the treatment of agitated behaviour in patients with dementia. Arch Gerontol Geriatr Suppl. 2001;33:159–62. [PubMed] [Google Scholar]

130. Ramadan FH, Naughton BJ, Bassanelli AG. Treatment of verbal agitation with a selective serotonin reuptake inhibitor. J Geriatr Psychiatry Neurol. 2000;13:56–9. [PubMed] [Google Scholar]

131. Pollock BG, Mulsant BH, Rosen J, Sweet RA, Mazumdar S, Bharucha A, et al. Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioural disturbances in hospitalized demented patients. Am J Psychiatry. 2002;159:460–5. [PubMed] [Google Scholar]

132. Kurita M, Sato T, Nishino S, Ohtomo K, Shirakawa H, Mashiko H, et al. Effects of fluvoxamine on behavioral and psychological symptoms of dementia in Alzheimer’s disease: a report of three cases. Fukushima J Med Sci. 2006;52:143–8. [PubMed] [Google Scholar]

133. López-Pousa S, Garre-Olmo J, Vilalta-Franch J, Turon-Estrada A, Pericot-Nierga I. Trazodone for Alzheimer’s disease: a naturalistic follow-up study. Arch Gerontol Geriatr. 2008;47:207–15. [PubMed] [Google Scholar]

134. Teri L, Logsdon RG, Peskind E, Raskind M, Weiner MF, Tractenberg RE, et al. Treatment of agitation in AD: A randomized, place-controlled clinical trial. Neurology. 2000;55:1271–8. [PubMed] [Google Scholar]

Which nursing intervention is most appropriate for a client with Alzheimer's disease who has frequent episodes emotional liability?

What is the nursing intervention for Alzheimer disease?

What is the most effective intervention for Alzheimer's disease?

What are some effective interventions in caring for a patient with dementia?